Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 11/2 cls
Alkermes (ALKS) Jefferies David Windley Price target Hold -18% $14.19
Windley lowered his target to $16 from $17 after ALKS reported fiscal 2Q08 revenue of $58.6M, which was below his $64.8M estimate. Windley also lowered his FY08 EPS estimate to $0.12 from $0.22 to account for $5-$10M in expected Vivitrol losses early next year due to a sales force reduction. Vivitrol naltrexone, an injectable sustained-release formulation of naltrexone in polylactide co-glycolide polymer microspheres, is approved to treat alcohol dependence.
AMAG Pharma (AMAG) Bear Stearns Mark Schoenebaum New Market outperform 5% $64.69
Schoenebaum believes that AMAG's ferumoxytol, which has completed a Phase III trial as an IV iron replacement therapy, has the right profile for the treatment of pre-dialysis patients with chronic kidney disease (CKD). He expects AMAG to submit an NDA by year end.
Amylin (AMLN) Banc of America Securities William Ho Price target Neutral -9% $43.15
Rodman Michael King Downgrade Market

Read the full 1697 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers